Status:
TERMINATED
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Lead Sponsor:
Center for International Blood and Marrow Transplant Research
Collaborating Sponsors:
M.D. Anderson Cancer Center
Conditions:
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to find out what effects (good and bad) a stem cell transplant from an unrelated donor will have for patients with kidney cancer that has spread to other parts of the body...
Detailed Description
Standard treatment for kidney cancer that has spread to other parts of the body may include immunotherapy (a therapy that uses the body's natural immune system to fight cancer) and cytokines (proteins...
Eligibility Criteria
Inclusion
- Diagnosis of metastatic (stage IV) renal cell carcinoma (RCC) predominately clear cell type
- Prior nephrectomy
- Available HLA-matched (8/8, 7/8) unrelated donor
- At least one prior immunotherapy; or immunotherapy + chemotherapy; or targeted therapy, for metastatic RCC.
- Adequate organ function
Exclusion
- Prior allogeneic stem cell transplantation
- RCC with histology other than clear cell type
- History or presence of brain metastasis
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00318110
Start Date
April 1 2006
End Date
March 1 2009
Last Update
July 26 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California - Los Angeles
Los Angeles, California, United States, 90095
2
Shands - University of Florida
Gainesville, Florida, United States, 32610
3
University of Minnesota
Minneapolis, Minnesota, United States, 55455
4
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104